A simple urine test may spot bladder cancer early — a trial puts it to the test

NCT ID NCT07735858

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial is developing a new, non-invasive urine test for bladder cancer. It uses a microfluidic chip to isolate tiny particles called exosomes from urine and analyze their genetic and protein content. The goal is to create a diagnostic model that can detect bladder cancer accurately without needing a tissue biopsy. The test will be developed in one group of patients and then validated in a separate group to see how well it performs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Liquid biopsy (urinary exosome analysis via microfluidic chip)
What this could lead to
If successful, this could provide a simple, non-invasive urine test to detect bladder cancer early, potentially reducing the need for invasive biopsies.
What could go wrong
This is an early-stage diagnostic model that needs validation in larger, diverse groups. The test may not be accurate enough to replace standard diagnosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.